Reagent, method and kit for detection of biological activity of glucagon-like peptide-1 (GLP-1)

Abstract

The invention relates to a reagent for detection of biological activity of glucagon-like peptide-1 (GLP-1). The reagent added into each 15 microliters of a detection sample comprises: 1, 35-45 microliters of a membrane reaction solution, 2, 15-25 microliters of a GLP-1 acceptor, 3, 10-20 microliters of a GLP-1 standard substance, 4, 5-15 microliters of sitgliptin phosphate, 5, 1-10 microliters of triphosadenine, 6, 1-10 microliters of guanosine triphosphate, 7, 5-15 microliters of 3-isobutyl-1-methylxanthine, 8, 1-10 microliters of bovine serum albumin, 9, 50-150 microliters of a biotin-labeled mouse anti-human cAMP monoclonal antibody, 10, a microwell plate coated with a goat anti-human cAMP polyclonal antibody, 11, 50-150 microliters of an avidin-labeled horseradish peroxidase, 12, 300-400 microliters of a PBS washing liquor, 13, 50-150 microliters of a chromogenic substrate, and 14, 50-150 microliters of a stop buffer. The GLP-1 acceptor is produced by genetic recombination, is convenient for purification and can reduce the batch difference of the reagent. The GLP-1 acceptor is used as a probe for capturing GLP-1 so that detection sensitivity is improved, biological activity can be directly determined, sensitivity is high, and practicality is strong.

Description

technical field [0001] The invention relates to a detection reagent in the field of medical testing, in particular to a detection reagent, detection method and kit for glucagon-like peptide-1 (glucagon-like peptide-1, GLP-1) biological activity. Background technique [0002] Diabetes is based on polygenic inheritance, coupled with the effects of environmental factors and autoimmunity, through an incompletely elucidated mechanism, causing insulin secretion disorders and insufficient insulin biological effects, resulting in hyperglycemia as the basic biochemical characteristics of sugar, A group of clinical syndromes characterized by disorders of fat, protein, water and electrolyte metabolism. In typical cases, symptoms of "three excesses and one deficiency" such as polyuria, polydipsia, polyphagia, and weight loss may appear. The chronic complications are mainly specific and non-specific microangiopathy and peripheral neuropathy. At present, diabetes has become the third maj...

AI Technical Summary

Problems solved by technology

Aiming at the limitation that GLP-1 analogues stay in the body for a short time in clinical practice and require daily injections, a GLP-1 mutant polypeptide with a longer half-life is provided. The GLP-1 mutant polypeptide has a longer half-life and does not Patients need to be injected every day, which can effectively improve the patient's compliance attitude

Images